You are here: Industry Insights > ALS

News List

Why Edaravone of Mitsubishi Tanabe is Excellent? PharmaSources/1℃
August 14, 2019
Edaravone of Mitsubishi Tanabe was approved for marketing in China on July 31, 2019, with the acceptance No.: JXHS1900047 and indication of amyotrophic lateral sclerosis (ALS).
Complete response letter given to ALS treatment for API concern europeanpharmaceuticalreview
July 23, 2019
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.
High BMI, Weight Gain Linked to Lasting Decrease in ALS Risk drugs
June 28, 2019
High BMI, Weight Gain Linked to Lasting Decrease in ALS Risk
Could Heavier Folks Be at Lower Risk for ALS? drugs
June 27, 2019
Could Heavier Folks Be at Lower Risk for ALS?
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS drugs
April 25, 2019
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS.
Kadimastem Announces the Completion of Cell Transplantation of AstroRx in ALS Patients americanpharmaceuticalreview
February 28, 2019
Kadimastem announced the completion of cell transplantation (AstroRx®) in 5 patients who were enrolled in Cohort A for its clinical trial in ALS....
Statins could protect against motor neurone disease, scientists suggest pharmaphorum
February 18, 2019
High cholesterol could be a risk factor in development of motor neurone disease, according to a study of genetic data by UK scientists.
Neurimmune’s anti-SOD1 antibody shows promise in ALS mouse studies fiercebiotech
January 02, 2019
Mutations in the gene SOD1 can cause the enzyme it encodes to fold in ways that are harmful to neurons—an abnormality that's responsible for about ....
EnClear Spins out of QurAlis americanpharmaceuticalreview
December 29, 2018
EnClear Therapies has spun-out from QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases. EnClear’s mission is to halt the progression of ....
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment for a Subtype of ALS americanpharmaceuticalreview
December 10, 2018
Biogen Inc and Ionis Pharmaceuticals, Inc. have announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to.....

Previous page 1 2 3 4 5 6 7 8 Next page